DarioHealth Appoints Olivier Jarry, Former Head of Diabetes Care at Bayer and Executive at Novartis and Bristol-Myers-Squibb, as President and Chief Commercial Officer

    Sep 5, 2018

    CAESAREA, Israel, Sept. 5, 2018 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, announced today that Olivier Jarry, a prominent global life sciences and consumer health executive, has joined the Company as President and Chief Commercial Officer. Mr. Jarry will be based in the U.S. and will lead DarioHealth's efforts relating to global revenue generation including B2B sales and data monetization. 

    Dario Health (PRNewsfoto/DarioHealth Corp.)

    Mr. Jarry brings to DarioHealth more than 30 years of experience improving health and living standards throughout Western and Eastern Europe, the Americas and Asia. He has created sustainable, profitable growth, organically and through M&A, in the life sciences, consumer health, and nutrition industries. Mr. Jarry has been serving on the Company's advisory board for the last 18 months as a business development and strategy consultant.

    As Global Business Head at Bayer Diabetes Care, he managed in excess of $1.4 billion in sales. At Novartis he headed four regions: Europe, India, Latin America, and Asia Pacific in consumer health products, generics and vaccines. Mr. Jarry has led corporate strategy and M&A at Novartis and Bayer, globally, as well as at Bristol-Myers-Squibb, regionally. He has negotiated M&A and alliance agreements worth up to $1.1 billion. He has also been on the executive team and/or is a co-founder at smaller publicly traded and private companies including Intrexon and three biotechnology companies. Mr. Jarry serves on numerous industry, corporate, and non–profit boards. He holds a TRIUM executive MBA from NYU Stern, LSE London, and HEC Paris, a MEng from the French Department of Defense and a MSc from Ecole Centrale de Paris. Mr. Jarry was an Air Force Lieutenant and Defense Engineer with the French military.

    Olivier Jarry commented, "Throughout my career, I have been committed to three primary goals in healthcare: improving medical outcomes, reducing costs, and enhancing the patient experience. In my view, DarioHealth delivers on all three by leveraging its digital health solutions to serve people living with chronic disease. I believe DarioHealth is positioned to become the clear leader in digital healthcare for diabetes. By potentially applying its technology to other chronic conditions and growing its global sales and distribution network, DarioHealth may emerge as a major player in the healthcare space, while improving the lives of people around the world. I am delighted to help the Company execute on its potential."

    Erez Raphael, Chief Executive Officer of DarioHealth stated, "We are pleased and honored that Olivier has joined DarioHealth. He has a very impressive track record of building global revenue through new markets at companies including some of the largest pharmaceutical companies in the world, as well as dynamic start-ups. Our entire global team is eager to work with Olivier, who will manage global commercialization, based out of our New York office."

    About DarioHealth Corp.

    DarioHealth Corp. (NASDAQ: DRIO) is a leading global digital health company serving its users with dynamic mobile health solutions. In today's day and age, knowledge of health and treatment is being democratized, and we believe people deserve to know everything about their own health and have the best tools to manage their condition. DarioHealth employs a revolutionary approach whereby harnessing big data, we have developed a novel method for chronic disease data management, empowering people to analyze and personalize self-diabetes management in a totally new way without having the disease slow them down. DarioHealth has a commercial office in New York with an R&D center in Caesarea, Israel. For more information, visit http://mydario.investorroom.com/.

    Cautionary Note Regarding Forward-Looking Statements

    This news release and the statements of representatives and partners of DarioHealth Corp. (the "Company") related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate," or "continue" are intended to identify forward-looking statements. For example, when the Company describes that it believes it is positioned to become the clear leader in digital healthcare for diabetes and that by applying its technology to other chronic conditions, and growing its global sales and distribution network, it may emerge as a major player in the healthcare space, it is using forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

    DarioHealth Corporate Contact: Joao Mendes-Roter, VP Marketing, joao@mydario.com, 1-914-775-5548

    DarioHealth Investor Relations Contact: Westwicke Partners, Dario@Westwicke.com, 1-443-213-0500

     

     

    SOURCE DarioHealth Corp.


    print email rss